Login Register Cart 0
Review Article

新辅助疗法对可切除的胰腺癌至关重要

卷 26, 期 40, 2019

页: [7196 - 7211] 页: 16

弟呕挨: 10.2174/0929867325666180413101722

价格: $65

摘要

背景：对新辅助疗法的益处的意识正在提高，但是对于可切除的胰腺癌患者，其作为最初的治疗选择仍存在争议，特别是对于那些没有高风险预后特征的患者。即使对于具有高风险特征的患者，他们也有可能接受新辅助治疗，但也没有标准的治疗方案。方法：在本综述中，我们通过搜索PubMed / MEDLINE，ClinicalTrials.gov，Web of Science和Cochrane库，检查了可切除胰腺癌患者新辅助治疗的可用数据，包括前瞻性研究，回顾性研究和正在进行的临床试。 。描述了筛选研究的特征和结果。结果：包括具有报告结果的回顾性和前瞻性研究以及正在进行的随机研究。对于可切除的胰腺癌患者，由于多模式治疗完成率的提高，新辅助疗法具有诸如提高生存率，降低合并症和死亡率的风险以及提高成本效益等优点。诸如FOLFIRINOX（亚叶酸，氟尿嘧啶，伊立替康和奥沙利铂）或吉西他滨加纳布紫杉醇等高活性方案被认为是可接受的治疗方案。此外，某些患者可以接受除FOLFIRINOX以外的含铂方案。正在探索其他疗法，例如化学放射疗法，免疫肿瘤药和靶向疗法，并高度期待其结果。结论：本综述强调了新辅助疗法对可切除胰腺癌的益处。一些方案目前是可以接受的，但是需要经过精心设计的临床试验的更多证据，或者应在多学科团队的仔细检查后使用。

关键词: 可切除的胰腺癌，新辅助疗法，新辅助化疗方案，新辅助化疗放疗，胰腺导管腺癌，新疗法。

« Previous Next »
[1]
Lewis, D.R.; Chen, H.S.; Cockburn, M.G.; Wu, X.C.; Stroup, A.M.; Midthune, D.N.; Zou, Z.; Krapcho, M.F.; Miller, D.G.; Feuer, E.J. Early estimates of SEER cancer incidence, 2014. Cancer, 2017, 123(13), 2524-2534.
[http://dx.doi.org/10.1002/cncr.30630] [PMID: 28195651]
[2]
Kamisawa, T.; Wood, L.D.; Itoi, T.; Takaori, K. Pancreatic cancer. Lancet, 2016, 388(10039), 73-85.
[http://dx.doi.org/10.1016/S0140-6736(16)00141-0] [PMID: 26830752]
[3]
NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Version 2, 2017. Available at: http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (Accessed Date: 29 March, 2017).
[4]
Khorana, A.A.; Mangu, P.B.; Berlin, J.; Engebretson, A.; Hong, T.S.; Maitra, A.; Mohile, S.G.; Mumber, M.; Schulick, R.; Shapiro, M.; Urba, S.; Zeh, H.J.; Katz, M.H.G. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update. J. Clin. Oncol., 2017, 35(20), 2324-2328.
[http://dx.doi.org/10.1200/JCO.2017.72.4948] [PMID: 28398845]
[5]
Seufferlein, T.; Bachet, J.B. Van, Cutsem, E.; Rougier, P. Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, 23(Suppl. 7), vii33-vii40.
[http://dx.doi.org/10.1093/annonc/mds224] [PMID: 22997452]
[6]
Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; Bennouna, J.; Bachet, J.B.; Khemissa-Akouz, F.; Péré-Vergé, D.; Delbaldo, C.; Assenat, E.; Chauffert, B.; Michel, P.; Montoto-Grillot, C.; Ducreux, M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med., 2011, 364(19), 1817-1825.
[http://dx.doi.org/10.1056/NEJMoa1011923] [PMID: 21561347]
[7]
Von, Hoff. D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, SA.; M.a, WW.; Saleh, M.N.; Harris, M.; Reni, M.; Dowden, S.; Laheru, D.; Bahary, N.; Ramanathan, R.K.; Tabernero, J.; Hidalgo, M.; Goldstein, D.; Van, Cutsem, E.; Wei, X.; Iglesias, J.; Renschler, M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med., 2013, 369(18), 1691-1703.
[http://dx.doi.org/10.1056/NEJMoa1304369] [PMID: 24131140]
[8]
Von, Hoff. D.D.; Ramanathan, R.K.; Borad, M.J.; Laheru, D.A.; Smith, L.S.; Wood, T.E.; Korn, R.L.; Desai, N.; Trieu, V.; Iglesias, J.L.; Zhang, H.; Soon-Shiong, P.; Shi, T.; Rajeshkumar, N.V.; Maitra, A.; Hidalgo, M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol., 2011, 29(34), 4548-4554.
[http://dx.doi.org/10.1200/JCO.2011.36.5742] [PMID: 21969517]
[9]
Frese, K.K.; Neesse, A.; Cook, N.; Bapiro, T.E.; Lolkema, M.P.; Jodrell, D.I.; Tuveson, D.A. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov., 2012, 2(3), 260-269.
[http://dx.doi.org/10.1158/2159-8290.CD-11-0242] [PMID: 22585996]
[10]
Hackert, T.; Sachsenmaier, M.; Hinz, U.; Schneider, L.; Michalski, C.W.; Springfeld, C.; Strobel, O.; Jäger, D.; Ulrich, A.; Büchler, M.W. Locally advanced pancreatic cancer: Neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann. Surg., 2016, 264(3), 457-463.
[http://dx.doi.org/10.1097/SLA.0000000000001850] [PMID: 27355262]
[11]
Nipp, R.D.; Zanconato, A.; Zheng, H.; Ferrone, C.R.; Lillemoe, K.D.; Wo, J.Y.; Hong, T.S.; Clark, J.W.; Ryan, D.P. Fernández-Del, Castillo, C. Predictors of early mortality after surgical resection of pancreatic adenocarcinoma in the era of neoadjuvant treatment. Pancreas, 2017, 46(2), 183-189.
[http://dx.doi.org/10.1097/MPA.0000000000000731] [PMID: 27846142]
[12]
Capello, M.; Lee, M.; Wang, H.; Babel, I.; Katz, M.H.; Fleming, J.B.; Maitra, A.; Wang, H.; Tian, W.; Taguchi, A.; Hanash, S.M. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J. Natl. Cancer Inst., 2015, 107(8) pii: djv132
[http://dx.doi.org/10.1093/jnci/djv132] [PMID: 26025324]
[13]
Wang-Gillam, A.; Li, C.P.; Bodoky, G.; Dean, A.; Shan, Y.S.; Jameson, G.; Macarulla, T.; Lee, K.H.; Cunningham, D.; Blanc, J.F.; Hubner, R.A.; Chiu, C.F.; Schwartsmann, G.; Siveke, J.T.; Braiteh, F.; Moyo, V.; Belanger, B.; Dhindsa, N.; Bayever, E. Von, Hoff, D.D.; Chen, L.T. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, 2016, 387(10018), 545-557.
[http://dx.doi.org/10.1016/S0140-6736(15)00986-1] [PMID: 26615328]
[14]
Okada, K.I.; Shimokawa, T.; Hirono, S.; Kawai, M.; Sho, M.; Satoi, S.; Matsumoto, I.; Eguchi, H.; Murakami, Y.; Yamada, S.; Doi, M.; Yamaue, H. Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer: A prospective multicenter phase II trial (NAC-GA Trial). Oncology, 2017, 93(5), 343-346.
[http://dx.doi.org/10.1159/000478660] [PMID: 28719890]
[15]
Alvarez, R.; Musteanu, M.; Garcia-Garcia, E.; Lopez-Casas, P.P.; Megias, D.; Guerra, C.; Muñoz, M.; Quijano, Y.; Cubillo, A.; Rodriguez-Pascual, J.; Plaza, C. de, Vicente, E.; Prados, S.; Tabernero, S.; Barbacid, M.; Lopez-Rios, F.; Hidalgo, M. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer, 2013, 109(4), 926-933.
[http://dx.doi.org/10.1038/bjc.2013.415] [PMID: 23907428]
[16]
Ielpo, B.; Duran, H.; Diaz, E.; Fabra, I.; Caruso, R.; Ferri, V.; Malavé, L.; Hidalgo, M.; Alvarez, R.; Plaza, C.; Quijano, Y.; Vicente, E. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur. J. Surg. Oncol., 2016, 42(9), 1394-1400.
[http://dx.doi.org/10.1016/j.ejso.2016.01.006] [PMID: 26899943]
[17]
Waddell, N.; Pajic, M.; Patch, A.M.; Chang, D.K.; Kassahn, K.S.; Bailey, P.; Johns, A.L.; Miller, D.; Nones, K.; Quek, K.; Quinn, M.C.; Robertson, A.J.; Fadlullah, M.Z.; Bruxner, T.J.; Christ, A.N.; Harliwong, I.; Idrisoglu, S.; Manning, S.; Nourse, C.; Nourbakhsh, E.; Wani, S.; Wilson, P.J.; Markham, E.; Cloonan, N.; Anderson, M.J.; Fink, J.L.; Holmes, O.; Kazakoff, S.H.; Leonard, C.; Newell, F.; Poudel, B.; Song, S.; Taylor, D.; Waddell, N.; Wood, S.; Xu, Q.; Wu, J.; Pinese, M.; Cowley, M.J.; Lee, H.C.; Jones, M.D.; Nagrial, A.M.; Humphris, J.; Chantrill, L.A.; Chin, V.; Steinmann, A.M.; Mawson, A.; Humphrey, E.S.; Colvin, E.K.; Chou, A.; Scarlett, C.J.; Pinho, A.V.; Giry-Laterriere, M.; Rooman, I.; Samra, J.S.; Kench, J.G.; Pettitt, J.A.; Merrett, N.D.; Toon, C.; Epari, K.; Nguyen, N.Q.; Barbour, A.; Zeps, N.; Jamieson, N.B.; Graham, J.S.; Niclou, S.P.; Bjerkvig, R.; Grützmann, R.; Aust, D.; Hruban, R.H.; Maitra, A.; Iacobuzio-Donahue, C.A.; Wolfgang, C.L.; Morgan, R.A.; Lawlor, R.T.; Corbo, V.; Bassi, C.; Falconi, M.; Zamboni, G.; Tortora, G.; Tempero, M.A.; Gill, A.J.; Eshleman, J.R.; Pilarsky, C.; Scarpa, A.; Musgrove, E.A.; Pearson, J.V.; Biankin, A.V.; Grimmond, S.M. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518(7540), 495-501.
[http://dx.doi.org/10.1038/nature14169] [PMID: 25719666]
[18]
Golcher, H.; Brunner, T.B.; Witzigmann, H.; Marti, L.; Bechstein, W.O.; Bruns, C.; Jungnickel, H.; Schreiber, S.; Grabenbauer, G.G.; Meyer, T.; Merkel, S.; Fietkau, R.; Hohenberger, W. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther. Onkol., 2015, 191(1), 7-16.
[http://dx.doi.org/10.1007/s00066-014-0737-7] [PMID: 25252602]
[19]
Golan, T.; Sella, T.; O’Reilly, E.M.; Katz, M.H.; Epelbaum, R.; Kelsen, D.P.; Borgida, A.; Maynard, H.; Kindler, H.; Friedmen, E.; Javle, M.; Gallinger, S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br. J. Cancer, 2017, 116(6), 697-702.
[http://dx.doi.org/10.1038/bjc.2017.19] [PMID: 28183138]
[20]
Golan, T.; Kanji, Z.S.; Epelbaum, R.; Devaud, N.; Dagan, E.; Holter, S.; Aderka, D.; Paluch-Shimon, S.; Kaufman, B.; Gershoni-Baruch, R.; Hedley, D.; Moore, M.J.; Friedman, E.; Gallinger, S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer, 2014, 111(6), 1132-1138.
[http://dx.doi.org/10.1038/bjc.2014.418] [PMID: 25072261]
[21]
OʼReilly. E.M.; Perelshteyn, A.; Jarnagin, W.R.; Schattner, M.; Gerdes, H.; Capanu, M.; Tang, LH.; LaValle, J.; Winston, C.; DeMatteo, R.P.; DʼAngelica, M.; Kurtz, R.C.; Abou-Alfa, G.K.; Klimstra, D.S.; Lowery, M.A.; Brennan, M.F.; Coit, D.G.; Reidy, D.L.; Kingham, T.P.; Allen, P.J. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann. Surg., 2014, 260(1), 142-148.
[http://dx.doi.org/10.1097/SLA.0000000000000251] [PMID: 24901360]
[22]
Uesaka, K.; Boku, N.; Fukutomi, A.; Okamura, Y.; Konishi, M.; Matsumoto, I.; Kaneoka, Y.; Shimizu, Y.; Nakamori, S.; Sakamoto, H.; Morinaga, S.; Kainuma, O.; Imai, K.; Sata, N.; Hishinuma, S.; Ojima, H.; Yamaguchi, R.; Hirano, S.; Sudo, T.; Ohashi, Y. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet, 2016, 388(10041), 248-257.
[http://dx.doi.org/10.1016/S0140-6736(16)30583-9] [PMID: 27265347]
[23]
Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; Falconi, M.; Pederzoli, P.; Pap, A.; Spooner, D.; Kerr, D.J.; Büchler, M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med., 2004, 350(12), 1200-1210.
[http://dx.doi.org/10.1056/NEJMoa032295] [PMID: 15028824]
[24]
Fujii, T.; Satoi, S.; Yamada, S.; Murotani, K.; Yanagimoto, H.; Takami, H.; Yamamoto, T.; Kanda, M.; Yamaki, S.; Hirooka, S.; Kon, M.; Kodera, Y. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. J. Gastroenterol., 2017, 52(1), 81-93.
[http://dx.doi.org/10.1007/s00535-016-1217-x] [PMID: 27169844]
[25]
Satoi, S.; Yanagimoto, H.; Yamamoto, T.; Ohe, C.; Miyasaka, C.; Uemura, Y.; Hirooka, S.; Yamaki, S.; Ryota, H.; Michiura, T.; Inoue, K.; Matsui, Y.; Tanigawa, N.; Kon, M. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Surg. Today, 2017, 47(1), 84-91.
[http://dx.doi.org/10.1007/s00595-016-1358-9] [PMID: 27262676]
[26]
Papalezova, K.T.; Tyler, D.S.; Blazer, D.G.; Clary, B.M.; Czito, B.G.; Hurwitz, H.I.; Uronis, H.E.; Pappas, T.N.; Willett, C.G.; White, R.R. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer. J. Surg. Oncol., 2012, 106(1), 111-118.
[http://dx.doi.org/10.1007/s00595-016-1358-9] [PMID: 27262676]
[27]
Oettle, H.; Neuhaus, P.; Hochhaus, A.; Hartmann, J.T.; Gellert, K.; Ridwelski, K.; Niedergethmann, M.; Zülke, C.; Fahlke, J.; Arning, M.B.; Sinn, M.; Hinke, A.; Riess, H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA, 2013, 310(14), 1473-1481.
[http://dx.doi.org/10.1001/jama.2013.279201] [PMID: 24104372]
[28]
Burris, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D. Von, Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15(6), 2403-2413.
[http://dx.doi.org/10.1200/JCO.1997.15.6.2403] [PMID: 9196156]
[29]
Lee, S.H.; Kang, C.M.; Kim, H.; Hwang, H.K.; Song, S.Y.; Seong, J.; Kim, M.J.; Lee, W.J. Pathological complete remission of pancreatic cancer following neoadjuvant chemoradiation therapy: Not the end of battles. Medicine, 2015, 94(52), e2168
[http://dx.doi.org/10.1200/JCO.1997.15.6.2403] [PMID: 9196156]
[30]
Bird, N.T.; Elmasry, M.; Jones, R.; Psarelli, E.; Dodd, J.; Malik, H.; Greenhalf, W.; Kitteringham, N.; Ghaneh, P.; Neoptolemos, J.P.; Palmer, D. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br. J. Surg., 2017, 104(4), 328-336.
[http://dx.doi.org/10.1002/bjs.10482] [PMID: 28199010]
[31]
Tajima, H.; Kitagawa, H.; Tsukada, T.; Nakanuma, S.; Okamoto, K.; Sakai, S.; Makino, I.; Furukawa, H.; Nakamura, K.; Hayashi, H.; Oyama, K.; Inokuchi, M.; Nakagawara, H.; Miyashita, T.; Fujita, H.; Itoh, H.; Takamura, H.; Ninomiya, I.; Fushida, S.; Fujimura, T.; Ohta, T. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Mol. Clin. Oncol., 2013, 1(4), 768-772.
[http://dx.doi.org/10.3892/mco.2013.133] [PMID: 24649244]
[32]
D’Angelo, F.A.; Antolino, L.; La Rocca, M.; Petrucciani, N.; Magistri, P.; Aurello, P.; Ramacciato, G. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. Med. Oncol., 2016, 33(3), 28.
[http://dx.doi.org/10.1007/s12032-016-0742-z] [PMID: 26883935]
[33]
Wang, W.Q.; Liu, L.; Xu, H.X.; Wu, C.T.; Xiang, J.F.; Xu, J.; Liu, C.; Long, J.; Ni, Q.X.; Yu, X.J. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br. J. Surg., 2016, 103(9), 1189-1199.
[http://dx.doi.org/10.1002/bjs.10187] [PMID: 27256393]
[34]
Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J. Clin. Oncol., 2007, 25(15), 1960-1966.
[http://dx.doi.org/10.1200/JCO.2006.07.9525] [PMID: 17452677]
[35]
Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; Kohrt, H.E.; Horn, L.; Lawrence, D.P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P.S.; Mellman, I.; Chen, D.S.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528), 563-567.
[http://dx.doi.org/10.1038/nature14011] [PMID: 25428504]
[36]
Dong, X.; Li, Y.; Chang, P.; Hess, K.R.; Abbruzzese, J.L.; Li, D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Molecular carcinogenesis, 2012, 51(6), 491-499.
[http://dx.doi.org/10.1002/mc.20817] [PMID: 21681824]
[37]
Beatty, G.L.; Chiorean, E.G.; Fishman, M.P.; Saboury, B.; Teitelbaum, U.R.; Sun, W.; Huhn, R.D.; Song, W.; Li, D.; Sharp, L.L.; Torigian, D.A.; O’Dwyer, P.J.; Vonderheide, R.H. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 2011, 331(6024), 1612-1616.
[http://dx.doi.org/10.1126/science.1198443] [PMID: 21436454]
[38]
Xu, C.P.; Xue, X.J.; Liang, N.; Xu, D.G.; Liu, F.J.; Yu, X.S.; Zhang, J.D. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol., 2014, 140(4), 549-559.
[http://dx.doi.org/10.1007/s00432-013-1572-4] [PMID: 24370686]
[39]
Lutfi, W.; Talamonti, M.S.; Kantor, O.; Wang, C.H.; Stocker, S.J.; Bentrem, D.J.; Roggin, K.K.; Winchester, D.J.; Marsh, R.; Prinz, R.A.; Baker, M.S. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Am. J. Surg., 2017, 213(3), 521-525.
[http://dx.doi.org/10.1016/j.amjsurg.2016.11.039] [PMID: 28089341]
[40]
Hong, T.S.; Ryan, D.P.; Borger, D.R.; Blaszkowsky, L.S.; Yeap, B.Y.; Ancukiewicz, M.; Deshpande, V.; Shinagare, S.; Wo, J.Y.; Boucher, Y.; Wadlow, R.C.; Kwak, E.L.; Allen, J.N.; Clark, J.W.; Zhu, A.X.; Ferrone, C.R.; Mamon, H.J.; Adams, J.; Winrich, B.; Grillo, T.; Jain, R.K.; DeLaney, T.F. Fernandez-del, Castillo, C.; Duda, D.G. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys., 2014, 89(4), 830-838.
[http://dx.doi.org/10.1016/j.ijrobp.2014.03.034] [PMID: 24867540]
[41]
Cooper, A.B.; Parmar, A.D.; Riall, T.S.; Hall, B.L.; Katz, M.H.; Aloia, T.A.; Pitt, H.A. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J. Gastrointest. Surg., 2015, 19(1), 80-86. discussion 86-87.
[http://dx.doi.org/10.1007/s11605-014-2620-3] [PMID: 25091851]
[42]
Casadei, R. Di, Marco, M.; Ricci, C.; Santini, D.; Serra, C.; Calculli, L.; D’Ambra, M.; Guido, A.; Morselli-Labate, A.M.; Minni, F. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J. Gastrointest. Surg., 2015, 19(10), 1802-1812.
[http://dx.doi.org/10.1007/s11605-015-2890-4] [PMID: 26224039]
[43]
Fathi, A.; Christians, K.K.; George, B.; Ritch, P.S.; Erickson, B.A.; Tolat, P.; Johnston, F.M.; Evans, D.B.; Tsai, S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J. Gastrointest. Oncol., 2015, 6(4), 418-429.
[http://dx.doi.org/10.3978/j.issn.2078-6891.2015.053] [PMID: 26261728]
[44]
Olaparib effective in four advanced cancers. Cancer Discov., 2015, 5(1), Of3.
[http://dx.doi.org/10.1158/2159-8290.CD-NB2014-176] [PMID: 25583815]
[45]
Pihlak, R.; Valle, J.W.; McNamara, M.G. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget, 2017, 8(42), 73240-73257.
[http://dx.doi.org/10.18632/oncotarget.17291] [PMID: 29069866]
[46]
Herrera, F.G.; Bourhis, J.; Coukos, G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J. Clin., 2017, 67(1), 65-85.
[http://dx.doi.org/10.3322/caac.21358] [PMID: 27570942]
[47]
Klug, F.; Prakash, H.; Huber, P.E.; Seibel, T.; Bender, N.; Halama, N.; Pfirschke, C.; Voss, R.H.; Timke, C.; Umansky, L.; Klapproth, K.; Schakel, K.; Garbi, N.; Jager, D.; Weitz, J.; Schmitz-Winnenthal, H.; Hammerling, G.J.; Beckhove, P. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell, 2013, 24(5), 589-602.
[http://dx.doi.org/10.1016/j.ccr.2013.09.014] [PMID: 24209604]
[48]
Bilimoria, K.Y.; Bentrem, D.J.; Ko, C.Y.; Tomlinson, J.S.; Stewart, A.K.; Winchester, D.P.; Talamonti, M.S. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer, 2007, 110(6), 1227-1234.
[http://dx.doi.org/10.1002/cncr.22916] [PMID: 17654662]
[49]
Tzeng, C.W. Tran, Cao, H.S.; Lee, J.E.; Pisters, P.W.; Varadhachary, G.R.; Wolff, R.A.; Abbruzzese, J.L.; Crane, C.H.; Evans, D.B.; Wang, H.; Abbott, D.E.; Vauthey, J.N.; Aloia, T.A.; Fleming, J.B.; Katz, MH. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J. Gastrointest. Surg., 2014, 18(1), 16-24.
[http://dx.doi.org/10.1007/s11605-013-2412-1] [PMID: 24241967]
[50]
Mornex, F.; Girard, N.; Delpero, J.R.; Partensky, C. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment. Semin. Radiat. Oncol., 2005, 15(4), 226-234.
[http://dx.doi.org/10.1016/j.semradonc.2005.04.008] [PMID: 16183476]
[51]
Du, L.; Wang-Gillam, A. Trends in neoadjuvant approaches in pancreatic cancer. J. Natl. Compr. Canc. Netw., 2017, 15(8), 1070-1077.
[http://dx.doi.org/10.6004/jnccn.2017.0134] [PMID: 28784867]
[52]
Reni, M. Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing? World J. Gastroenterol., 2010, 16(39), 4883-4887.
[http://dx.doi.org/10.3748/wjg.v16.i39.4883] [PMID: 20954273]
[53]
Silvestris, N.; Longo, V.; Cellini, F.; Reni, M.; Bittoni, A.; Cataldo, I.; Partelli, S.; Falconi, M.; Scarpa, A.; Brunetti, O.; Lorusso, V.; Santini, D.; Morganti, A.; Valentini, V.; Cascinu, S. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Crit. Rev. Oncol. Hematol., 2016, 98, 309-324.
[http://dx.doi.org/10.1016/j.critrevonc.2015.11.016] [PMID: 26653573]
[54]
Mokdad, A.A.; Minter, R.M.; Zhu, H.; Augustine, M.M.; Porembka, M.R.; Wang, S.C.; Yopp, A.C.; Mansour, J.C.; Choti, M.A.; Polanco, P.M. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J. Clin. Oncol., 2017, 35(5), 515-522.
[http://dx.doi.org/10.1200/JCO.2016.68.5081] [PMID: 27621388]
[55]
Jiang, H.; Du, C.; Cai, M.; He, H.; Chen, C.; Qiu, J.; Wu, H. An evaluation of neoadjuvant chemoradiotherapy for patients with resectable pancreatic ductal adenocarcinoma. HPB Surg., 2013, 2013298726
[http://dx.doi.org/10.1155/2013/298726] [PMID: 23864756]
[56]
Tachezy, M.; Gebauer, F.; Petersen, C.; Arnold, D.; Trepel, M.; Wegscheider, K.; Schafhausen, P.; Bockhorn, M.; Izbicki, J.R.; Yekebas, E. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer, 2014, 14, 411.
[http://dx.doi.org/10.1186/1471-2407-14-411] [PMID: 24906700]
[57]
Barbas, A.S.; Turley, R.S.; Ceppa, E.P.; Reddy, S.K.; Blazer, D.G.; Clary, B.M.; Pappas, T.N.; Tyler, D.S.; White, R.R.; Lagoo, S.A. Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. J. Am. Geriatr. Soc., 2012, 60(2), 344-350.
[http://dx.doi.org/10.1111/j.1532-5415.2011.03785.x] [PMID: 22211710]
[58]
Mirkin, K.A.; Hollenbeak, C.S.; Wong, J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A prospective cohort study involving 18, 332 patients from the national cancer data base. Int. J. Surg., 2016, 34, 96-102.
[http://dx.doi.org/10.1016/j.ijsu.2016.08.523] [PMID: 27573691]
[59]
Bergquist, J.R.; Puig, C.A.; Shubert, C.R.; Groeschl, R.T.; Habermann, E.B.; Kendrick, M.L.; Nagorney, D.M.; Smoot, R.L.; Farnell, M.B.; Truty, M.J. Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy, a national cancer database study. J. Am. Coll. Surg., 2016, 223(1), 52-65.
[http://dx.doi.org/10.1016/j.jamcollsurg.2016.02.009] [PMID: 27049786]
[60]
Chatterjee, D.; Rashid, A.; Wang, H.; Katz, M.H.; Wolff, R.A.; Varadhachary, G.R.; Lee, J.E.; Pisters, P.W.; Gomez, H.F.; Abbruzzese, J.L.; Fleming, J.B.; Wang, H. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am. J. Surg. Pathol., 2012, 36(4), 552-559.
[http://dx.doi.org/10.1097/PAS.0b013e318240c1c0] [PMID: 22301496]
[61]
Fischer, L.K.; Katz, M.H.; Lee, S.M.; Liu, L.; Wang, H.; Varadhachary, G.R.; Wolff, R.A.; Lee, J.E.; Maitra, A.; Roland, C.L.; Fleming, J.B.; Estrella, J.; Rashid, A.; Wang, H. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology, 2016, 68(2), 210-220.
[http://dx.doi.org/10.1111/his.12732] [PMID: 25945396]
[62]
Schorn, S.; Demir, I.E.; Reyes, C.M.; Saricaoglu, C.; Samm, N.; Schirren, R.; Tieftrunk, E.; Hartmann, D.; Friess, H.; Ceyhan, G.O. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat. Rev., 2017, 55, 96-106.
[http://dx.doi.org/10.1016/j.ctrv.2017.03.003] [PMID: 28342938]
[63]
Ferrone, C.R.; Marchegiani, G.; Hong, T.S.; Ryan, D.P.; Deshpande, V.; McDonnell, E.I.; Sabbatino, F.; Santos, D.D.; Allen, J.N.; Blaszkowsky, L.S.; Clark, J.W.; Faris, J.E.; Goyal, L.; Kwak, E.L.; Murphy, J.E.; Ting, D.T.; Wo, J.Y.; Zhu, A.X.; Warshaw, A.L.; Lillemoe, K.D. Fernández-del, Castillo, C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann. Surg., 2015, 261(1), 12-17.
[http://dx.doi.org/10.1097/SLA.0000000000001322] [PMID: 28486290]
[64]
Roland, C.L.; Yang, A.D.; Katz, M.H.; Chatterjee, D.; Wang, H.; Lin, H.; Vauthey, J.N.; Pisters, P.W.; Varadhachary, G.R.; Wolff, R.A.; Crane, C.H.; Lee, J.E.; Fleming, J.B. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann. Surg. Oncol., 2015, 22(4), 1168-1175.
[http://dx.doi.org/10.1245/s10434-014-4192-6] [PMID: 25352267]
[65]
Barnes, C.A.; Krepline, A.N.; Aldakkak, M.; Clarke, C.N.; Christians, K.K.; Khan, A.H.; Hunt, B.C.; Ritch, P.S.; George, B.; Hall, W.A.; Erickson, B.A.; Evans, D.B.; Tsai, S. Is adjuvant therapy necessary for all patients with localized pancreatic cancer who have received neoadjuvant therapy? J. Gastrointest. Surg., 2017, 21(11), 1793-1803.
[http://dx.doi.org/10.1007/s11605-017-3544-5] [PMID: 28849366]
[66]
Cooper, A.B.; Holmes, H.M. des, B.J.K.; etCooper, A.B.; Holmes, H.M.; des, Bordes, J.K.; Fogelman, D.; Parker, N.H.; Lee, J.E.; Aloia, T.A.; Vauthey, J.N.; Fleming, J.B.; Katz, M.H. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J. Am. Coll. Surg., 2014, 219(1), 111-120.
[http://dx.doi.org/10.1016/j.jamcollsurg.2014.02.023] [PMID: 24856952]
[67]
Abbott, D.E.; Tzeng, C.W.; Merkow, R.P.; Cantor, S.B.; Chang, G.J.; Katz, M.H.; Bentrem, D.J.; Bilimoria, K.Y.; Crane, C.H.; Varadhachary, G.R.; Abbruzzese, J.L.; Wolff, R.A.; Lee, J.E.; Evans, D.B.; Fleming, J.B. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery first approach in the treatment of pancreatic head adenocarcinoma. Ann. Surg. Oncol., 2013, 20(Suppl. 3), S500-S508.
[http://dx.doi.org/10.1245/s10434-013-2882-0] [PMID: 23397153]
[68]
Gillen, S.; Schuster, T.; Meyer, Z. Büschenfelde, C.; Friess, H.; Kleeff, J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med., 2010, 7(4)e1000267
[http://dx.doi.org/10.1371/journal.pmed.1000267] [PMID: 20422030]
[69]
Sharma, G.; Whang, E.E.; Ruan, D.T.; Ito, H. Efficacy of neoadjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma: a decision analysis. Ann. Surg. Oncol., 2015, 22(Suppl. 3), S1229-S1237.
[http://dx.doi.org/10.1245/s10434-015-4711-0] [PMID: 26152276]
[70]
Du, L.; DeFoe, M.; Ruzinova, M.B.; Olsen, J.R.; Wang-Gillam, A. Perioperative therapy for surgically resectable pancreatic adenocarcinoma. Hematol. Oncol. Clin. North Am., 2015, 29(4), 717-726.
[http://dx.doi.org/10.1016/j.hoc.2015.04.011] [PMID: 26226906]
[71]
Evans, D.B.; Varadhachary, G.R.; Crane, C.H.; Sun, C.C.; Lee, J.E.; Pisters, P.W.; Vauthey, J.N.; Wang, H.; Cleary, K.R.; Staerkel, G.A.; Charnsangavej, C.; Lano, E.A.; Ho, L.; Lenzi, R.; Abbruzzese, J.L.; Wolff, R.A. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol., 2008, 26(21), 3496-3502.
[http://dx.doi.org/10.1200/JCO.2007.15.8634] [PMID: 18640930]
[72]
Boone, B.A.; Steve, J.; Zenati, M.S.; Hogg, M.E.; Singhi, A.D.; Bartlett, D.L.; Zureikat, A.H.; Bahary, N.; Zeh, H.J. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann. Surg. Oncol., 2014, 21(13), 4351-4358.
[http://dx.doi.org/10.1245/s10434-014-3842-z] [PMID: 25092157]
[73]
Christians, K.K.; Heimler, J.W.; George, B.; Ritch, P.S.; Erickson, B.A.; Johnston, F.; Tolat, P.P.; Foley, W.D.; Evans, D.B.; Tsai, S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery, 2016, 159(3), 893-900.
[http://dx.doi.org/10.1016/j.surg.2015.09.018] [PMID: 26602840]

Rights & Permissions Print Cite
Article Metrics
54
5
© 2024 Bentham Science Publishers | Privacy Policy